Ladarixin Uses, Dosage, Side Effects and more
Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).
| Trade Name | Ladarixin |
| Generic | Ladarixin |
| Ladarixin Other Names | Ladarixin |
| Type | |
| Formula | C11H12F3NO6S2 |
| Weight | Average: 375.33 Monoisotopic: 375.005813947 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
